Mesa Laboratories, Inc. Revises Earnings Announcement date for Unaudited Fourth Quarter and Full Fiscal Year 2024 Results

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

LAKEWOOD, Colo., May 31, 2024 (GLOBE NEWSWIRE) — Mesa Laboratories, Inc. (“Mesa”) (NASDAQ:MLAB) will not issue its 2024 financial results for the fourth quarter and the fiscal year ending March 31, 2024 today as previously communicated. The earnings announcement has been delayed as we work to finalize our year end audit which is focused on finalizing the calculations and technical accounting for previously-announced impairments of long-lived assets and goodwill related to our Clinical Genomics and Biopharmaceutical Development divisions and the purchase accounting associated with the acquisition of GKE.

Mesa’s Form 10-K filing deadline with the SEC is June 14, 2024.

About Mesa Laboratories, Inc.

Mesa is a global leader in the design and manufacture of life sciences tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world.

For more information about the Company, please visit our website at www.mesalabs.com.

CONTACT: CONTACT: Gary Owens, President and CEO, or John Sakys, CFO, both of Mesa Laboratories, Inc., +1-303-987-8000

Staff

Recent Posts

Bay Area Cognitive Behavioral Therapy Center Expands Treatment Offerings with Acceptance and Commitment Therapy

Bay Area Therapy Center Expand Treatment Options Offering Comprehensive Mental Health Services in San FranciscoSAN…

20 hours ago

Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease

ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease New…

20 hours ago

Co-Diagnostics, Inc. Announces Intention to Submit Enhanced Version of COVID-19 Test to FDA for 510(k) Clearance

The Company is withdrawing current submission based on FDA feedback related to shelf-life stability of…

1 day ago

ZEISS Shapes the Future of Metrology with Cutting-Edge Technologies Revealed at Event

ZEISS Industrial Quality Solutions will host its first-ever digital launch event for the USA and…

1 day ago

The OhmX RAMP UP Grant Awarded to 15 Laboratories to Advance Genomic Research

PROVIDENCE, R.I., Feb. 21, 2025 /PRNewswire/ -- Nabsys 2.0, LLC (Nabsys) and Hitachi High-Tech America,…

2 days ago